NO20092726L - Frysetorket, injiserbar, framasoytisk kombinasjon av halvsyntetiske vincaalkoider og karbohydrater som er stabile ved romtemperatur - Google Patents

Frysetorket, injiserbar, framasoytisk kombinasjon av halvsyntetiske vincaalkoider og karbohydrater som er stabile ved romtemperatur

Info

Publication number
NO20092726L
NO20092726L NO20092726A NO20092726A NO20092726L NO 20092726 L NO20092726 L NO 20092726L NO 20092726 A NO20092726 A NO 20092726A NO 20092726 A NO20092726 A NO 20092726A NO 20092726 L NO20092726 L NO 20092726L
Authority
NO
Norway
Prior art keywords
freeze
semi
stable
room temperature
dried
Prior art date
Application number
NO20092726A
Other languages
English (en)
Inventor
Elie Leverd
Joel Bougaret
Marie-Dominique Ibarra
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38293420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092726(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20092726L publication Critical patent/NO20092726L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske sammensetninger som består av et semisyntetisk derivat av vinkaalkaloid, stabilt ved romtemperatur, hvori nevnte derivat er tilstede i form av et frysetørket produkt oppnådd i nærvær av minst ett karbohydrat.
NO20092726A 2006-12-29 2009-07-20 Frysetorket, injiserbar, framasoytisk kombinasjon av halvsyntetiske vincaalkoider og karbohydrater som er stabile ved romtemperatur NO20092726L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0656044A FR2910812B1 (fr) 2006-12-29 2006-12-29 Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
US89705907P 2007-01-24 2007-01-24
PCT/EP2007/064612 WO2008080968A1 (en) 2006-12-29 2007-12-28 Freeze-dried injectable pharmaceutical combination of semisynthetic vinca alkaloids and carbohydrate stable at room temperature

Publications (1)

Publication Number Publication Date
NO20092726L true NO20092726L (no) 2009-07-20

Family

ID=38293420

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092726A NO20092726L (no) 2006-12-29 2009-07-20 Frysetorket, injiserbar, framasoytisk kombinasjon av halvsyntetiske vincaalkoider og karbohydrater som er stabile ved romtemperatur

Country Status (24)

Country Link
US (1) US8304424B2 (no)
EP (1) EP2120934B1 (no)
JP (1) JP2010514737A (no)
KR (1) KR20090097883A (no)
CN (1) CN101534821B (no)
AR (1) AR064715A1 (no)
AU (1) AU2007341231B2 (no)
BR (1) BRPI0722076A2 (no)
CA (1) CA2673232A1 (no)
CL (1) CL2007003838A1 (no)
FR (1) FR2910812B1 (no)
HK (1) HK1130439A1 (no)
IL (1) IL199556A (no)
MA (1) MA30892B1 (no)
MX (1) MX2009006949A (no)
NO (1) NO20092726L (no)
NZ (1) NZ576583A (no)
RU (1) RU2449791C2 (no)
SA (1) SA07280720B1 (no)
TN (1) TN2009000258A1 (no)
TW (1) TWI415631B (no)
UA (1) UA96977C2 (no)
WO (1) WO2008080968A1 (no)
ZA (1) ZA200903115B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102151249A (zh) * 2010-02-11 2011-08-17 石药集团中奇制药技术（石家庄）有限公司 一种长春氟宁的药用组合物
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CN102772373B (zh) * 2011-05-11 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 一种注射用酒石酸长春瑞滨粉针剂及其制备方法
EP3843885A1 (en) * 2018-08-31 2021-07-07 FUJIFILM Irvine Scientific, Inc. Venting system for a mixing apparatus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170152B (it) * 1982-07-19 1987-06-03 Lilly Co Eli Miglioramenti a o riguardanti formulazioni di vinca-alcaloidi
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
JPH02290822A (ja) * 1989-04-04 1990-11-30 Eli Lilly & Co 医薬製剤
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
PL205936B1 (pl) * 2002-02-22 2010-06-30 Schering Corp Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
CN103948545B (zh) * 2004-05-03 2017-10-03 益普生生物制药公司 用于药物输送的脂质体
ES2434944T5 (es) * 2005-03-14 2022-10-20 Wyeth Llc Composiciones de tigeciclina y procedimientos de preparación

Also Published As

Publication number Publication date
RU2009128327A (ru) 2011-02-10
TW200833369A (en) 2008-08-16
UA96977C2 (ru) 2011-12-26
MA30892B1 (fr) 2009-11-02
AR064715A1 (es) 2009-04-22
RU2449791C2 (ru) 2012-05-10
CN101534821A (zh) 2009-09-16
EP2120934B1 (en) 2014-05-07
EP2120934A1 (en) 2009-11-25
ZA200903115B (en) 2010-04-28
FR2910812A1 (fr) 2008-07-04
NZ576583A (en) 2012-01-12
JP2010514737A (ja) 2010-05-06
IL199556A (en) 2014-09-30
KR20090097883A (ko) 2009-09-16
US8304424B2 (en) 2012-11-06
SA07280720B1 (ar) 2012-02-07
CL2007003838A1 (es) 2008-07-04
AU2007341231A1 (en) 2008-07-10
US20100087473A1 (en) 2010-04-08
TWI415631B (zh) 2013-11-21
AU2007341231B2 (en) 2013-03-21
CA2673232A1 (en) 2008-07-10
HK1130439A1 (en) 2009-12-31
FR2910812B1 (fr) 2009-03-20
WO2008080968A1 (en) 2008-07-10
CN101534821B (zh) 2012-01-25
MX2009006949A (es) 2009-07-14
BRPI0722076A2 (pt) 2014-04-08
TN2009000258A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
NO20092726L (no) Frysetorket, injiserbar, framasoytisk kombinasjon av halvsyntetiske vincaalkoider og karbohydrater som er stabile ved romtemperatur
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
NO20084334L (no) Farmasoytiske sammensetninger
MX2010006224A (es) Composicion de engomado para lana mineral que comprende un monosacarido y/o un polisacarido y un acido policarboxilico organico, y productos aislantes obtenidos.
NO20084253L (no) Tetrahydroisokinolinderivater for a forbedre hukommelsesfunksjon
MY159431A (en) Fibrous materials and compositions
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
CL2008003940A1 (es) Compuestos derivados de morfolino pirimidina sustituida; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de cancer, enfermedades inflamatorias, enfermedades obstructivas de las vias aereas, enfermedades inmunes o enfermedades cardiovasculares.
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
NO20080801L (no) Aerosolformulering for inhalering av beta-agonister
BR112012009135A2 (pt) composição polímera termoplástica
WO2007125103A3 (en) Benzamide glucokinase activators
ATE429906T1 (de) Trockene aripiprazolformulierungen
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
NO20074162L (no) Makrolider med anti-inflammatorisk aktivitet
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
BRPI0909055A2 (pt) composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto.
NO20081102L (no) Anvendelse av modifiserte trematerialer for fremstilling av gjenstander
NO20090562L (no) Sammensetninger for behandling av kroniske degenerative inflammatoriske tilstander
AR057174A1 (es) Mezclas
UY30745A1 (es) Inhibidor de factor xa
MX2011006567A (es) Formulaciones de fenilefrina con estabilidad mejorada.
ATE487488T1 (de) Neuartige antibiotische zusammensetzungen
RS20080410A (en) Dibenzyl amine compounds and derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application